

# Martin J Whitaker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8324483/publications.pdf>

Version: 2024-02-01

34  
papers

1,637  
citations

430442

18  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1762  
citing authors

#	ARTICLE	IF	CITATIONS
1	Applications of supercritical CO <sub>2</sub> in the fabrication of polymer systems for drug delivery and tissue engineering. <i>Advanced Drug Delivery Reviews</i> , 2008, 60, 373-387.	6.6	254
2	Supercritical fluid mixing: preparation of thermally sensitive polymer composites containing bioactive materials. <i>Chemical Communications</i> , 2001, , 109-110.	2.2	191
3	Three-Dimensional Bioactive and Biodegradable Scaffolds Fabricated by Surface-Selective Laser Sintering. <i>Advanced Materials</i> , 2005, 17, 327-330.	11.1	130
4	A Phase 2 Study of Chronocort, a Modified-Release Formulation of Hydrocortisone, in the Treatment of Adults With Classic Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1137-1145.	1.8	124
5	Human Osteoprogenitor Bone Formation Using Encapsulated Bone Morphogenetic Protein 2 in Porous Polymer Scaffolds. <i>Tissue Engineering</i> , 2004, 10, 1037-1045.	4.9	109
6	The production of protein-loaded microparticles by supercritical fluid enhanced mixing and spraying. <i>Journal of Controlled Release</i> , 2005, 101, 85-92.	4.8	100
7	Drug delivery goes supercritical. <i>Materials Today</i> , 2005, 8, 42-48.	8.3	91
8	Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1469-1477.	1.8	84
9	An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. <i>Clinical Endocrinology</i> , 2014, 80, 554-561.	1.2	83
10	Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2018, 178, 309-320.	1.9	54
11	Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. <i>Clinical Endocrinology</i> , 2018, 88, 21-29.	1.2	46
12	Mammalian cell survival and processing in supercritical CO <sub>2</sub> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7426-7431.	3.3	45
13	Plasticization and spraying of poly (DL-lactic acid) using supercritical carbon dioxide: control of particle size. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 1083-1090.	1.6	38
14	Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2855.	1.8	38
15	Quality of compounded hydrocortisone capsules used in the treatment of children. <i>European Journal of Endocrinology</i> , 2017, 177, 239-242.	1.9	37
16	Development and Testing in Healthy Adults of Oral Hydrocortisone Granules With Taste Masking for the Treatment of Neonates and Infants With Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1681-1688.	1.8	35
17	Supercritical fluid assisted melting of poly(ethylene glycol): a new solvent-free route to microparticles. <i>Journal of Materials Chemistry</i> , 2005, 15, 1148.	6.7	29
18	A Prospective Study of Children Aged 0-8 Years with CAH and Adrenal Insufficiency Treated with Hydrocortisone Granules. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1433-e1440.	1.8	22

#	ARTICLE	IF	CITATIONS
19	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 515-527.	1.6	15
20	Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child-appropriate administration fluids. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 133, 277-284.	2.0	15
21	Salivary Cortisone to Estimate Cortisol Exposure and Sampling Frequency Required Based on Serum Cortisol Measurements. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 765-772.	1.8	15
22	A Biopredictive In Vitro Approach for Assessing Compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing Vehicles. <i>Pharmaceutical Research</i> , 2020, 37, 203.	1.7	13
23	Accuracy of hydrocortisone dose administration via nasogastric tube. <i>Clinical Endocrinology</i> , 2019, 90, 66-73.	1.2	10
24	Development and verification of an endogenous PBPK model to inform hydrocortisone replacement dosing in children and adults with cortisol deficiency. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 165, 105913.	1.9	10
25	A model for measuring the health burden of classic congenital adrenal hyperplasia in adults. <i>Clinical Endocrinology</i> , 2016, 85, 361-398.	1.2	9
26	The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. <i>Clinical Endocrinology</i> , 2019, 91, 33-40.	1.2	9
27	Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. <i>Journal of Endocrinology</i> , 2020, 245, 207-218.	1.2	9
28	Adrenal Insufficiency in Young Children: a Mixed Methods Study of Parents' Experiences. <i>Journal of Genetic Counseling</i> , 2018, 27, 1447-1458.	0.9	7
29	Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2017, 176, 405-411.	1.9	6
30	Hydrocortisone Granules Are Bioequivalent When Sprinkled Onto Food or Given Directly on the Tongue. <i>Journal of the Endocrine Society</i> , 2019, 3, 847-856.	0.1	6
31	Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 819590.	1.6	2
32	Chronotherapy based on modified-release hydrocortisone to restore the physiological cortisol diurnal rhythm. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1-8.	3.0	1
33	Biorelevant dissolution and compatibility of hydrocortisone granules following exposure to water, breast-, whole- and artificial (formula) milk. <i>International Journal of Pharmaceutics</i> , 2018, 536, 519-520.	2.6	0
34	Response to Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2020, 183, L29-L30.	1.9	0